New injection shows promise for weight loss and diabetes control in early trial
NCT ID NCT04838405
Summary
This early-stage study tested a new injectable drug called CT-388 in overweight and obese adults, including some with type 2 diabetes. The main goal was to check if the drug was safe and how the body processed it. Researchers also looked at whether it helped with weight loss and improved blood sugar and insulin levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Carmot Clinical Research Unit 101
Perth, Western Australia, 6009, Australia
-
Carmot Clinical Research Unit 105
Monterrey, Nuevo León, 66260, Mexico
Conditions
Explore the condition pages connected to this study.